Drug Approvals, Data Presentations, Clinical Trials, New Appointments, and Corporate Events - Research Report on Johnson &

  Drug Approvals, Data Presentations, Clinical Trials, New Appointments, and
 Corporate Events - Research Report on Johnson & Johnson, Novo Nordisk, Isis,
                       Keryx, and The Medicines Company

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, October 9, 2013

NEW YORK, October 9, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Johnson &
Johnson (NYSE: JNJ), Novo Nordisk A/S (NYSE: NVO), Isis Pharmaceuticals, Inc.
(NASDAQ: ISIS), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), and The
Medicines Company (NASDAQ: MDCO). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Johnson & Johnson Research Report

On September 27, 2013, Janssen Pharmaceutical K.K., part of the Janssen
Pharmaceutical Companies of Johnson & Johnson, announced that the Japanese
Ministry of Health, Labour and Welfare (MHLW) has approved SOVRIAD (simeprevir
sodium), a new direct-acting antiviral agent (DAA), for the treatment of
genotype-1 chronic hepatitis C virus (HCV) infection. Commenting on the
approval, Bruce Goodwin, President, Janssen Pharmaceutical K.K., stated, "We
submitted SOVRIAD for regulatory approval in February of this year before any
other country in the world." Goodwin continued, "Data from the four Japanese
phase 3 CONCERTO studies that supported the new drug application were
presented in June at the Japan Society of Hepatology's 49th Annual Meeting in
Tokyo." He added, "SOVRIAD has the potential to offer a new standard treatment
option for people infected with chronic hepatitis C in Japan and around the
world." The Full Research Report on Johnson & Johnson - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/07a8_JNJ]

--

Novo Nordisk A/S Research Report

On September 27, 2013, Novo Nordisk A/S (Novo Nordisk) announced that phase 3
data from the investigational therapy IDegLira [Tresiba (insulin
degludec)/Victoza (liraglutide injection)] were presented at the 49th Annual
European Association for the Study of Diabetes (EASD) Congress. Professor
Stephen Gough, University of Oxford and Oxford University Hospitals NHS Trust,
lead investigator of the study, said, "The efficacy of IDegLira demonstrated
by the DUAL™ I data is exciting. It combines the clinical advantages, yet
mitigates the principal side effects of insulin degludec and liraglutide. DUAL
I shows how patients can achieve an average final HbA1c of 6.4% with no weight
gain and a low rate of hypoglycaemia." The Full Research Report on Novo
Nordisk A/S - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/fee1_NVO]

--

Isis Pharmaceuticals, Inc. Research Report

On October 3, 2013, Isis Pharmaceuticals, Inc. (Isis) announced that it dosed
the first infant in the 12 mg dose group in the Phase 2 study evaluating
ISIS-SMN[Rx] in infants with Type I spinal muscular atrophy (SMA). According
to the Company, the Phase 2 study is designed to allow Isis to define the
optimal dose for the larger Phase 2/3 study in infants and to provide safety
and tolerability data. Isis reported that it earned a $2 million milestone
payment from Biogen Idec associated with the advancement of this study, and
intends to complete this study and initiate the larger Phase 2/3 pivotal study
by early 2014. The Full Research Report on Isis Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/fcfc_ISIS]

--

Keryx Biopharmaceuticals Inc. Research Report

On October 2, 2013, Keryx Biopharmaceuticals Inc. (Keryx) announced the
appointment of Douglass H. Laidlaw, Ph.D. to the newly created position of
Director, Medical Affairs, with oversight of the creation and activities of
the Company's Medical Science Liaisons (MSL) team. Ron Bentsur, CEO OF Keryx,
commented, "We are excited to be welcoming Dr. Laidlaw to the Company. Dr.
Laidlaw brings a proven track record of success in the development and
leadership of a dedicated renal MSL team, strategic planning capabilities and
a vast network of relationships within the nephrology community. I am
confident that he will be an extraordinary asset as we build out our marketing
organization." The Full Research Report on Keryx Biopharmaceuticals Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/27d2_KERX]

--

The Medicines Company Research Report

On October 2, 2013, The Medicines Company announced that it has scheduled a
webcast of its upcoming Investor & Analyst Day on Wednesday, October 9, 2013,
from 8:30 a.m. to 12:00 p.m. ET. The Medicines Company reported that its
management will provide a comprehensive overview of the Company's medical,
operational, and financial strategies. The Company also informed that the
webcast can be accessed through a link provided at its website. The Full
Research Report on The Medicines Company - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.AnalystsCorner.com/r/full_research_report/5a84_MDCO]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America
 
Press spacebar to pause and continue. Press esc to stop.